Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients

J Dtsch Dermatol Ges. 2022 Apr;20(4):514-517. doi: 10.1111/ddg.14675. Epub 2022 Mar 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Brentuximab Vedotin / therapeutic use
  • Humans
  • Ki-1 Antigen
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Lymphoma, T-Cell, Cutaneous* / pathology
  • Retrospective Studies
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Ki-1 Antigen
  • Brentuximab Vedotin